LFCR - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Lifecore Biomedical

Lifecore Biomedical (LFCR) aims for leadership in the sterile injectables CDMO segment by integrating into the supply chains of medical behemoths. Year-over-year sales growth over the last 12 months clearly demonstrates revenue dynamics, where 0.00 captures the magnitude of this parameter. Business efficiency is based on the outsourcing of IT and raw materials, while high customer loyalty is ensured by strict FDA regulatory certification of the plants.

Stable capacity utilization for hyaluronic acid production and management expertise in contract manufacturing define the actual scale of Lifecore Biomedical (LFCR) operations. This metric measures the percentage change in revenue over a rolling twelve-month period relative to the same period last year, allowing the twelve-month annual revenue trajectory to assess the fundamental resilience of the business and eliminate the impact of short-term volatility.